HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kenichiro Itami Selected Research

CCR5 Receptors (CCR5 Receptor)

2/2015Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kenichiro Itami Research Topics

Disease

4Neoplasms (Cancer)
11/2020 - 01/2018
2Hyperuricemia
08/2011 - 04/2009
2Gout
08/2011 - 04/2009
1Hypoxia (Hypoxemia)
10/2023
1Neuroinflammatory Diseases
01/2023
1Lung Neoplasms (Lung Cancer)
01/2018
1Parkinson Disease (Parkinson's Disease)
04/2015
1Autoimmune Diseases (Autoimmune Disease)
02/2015
1AIDS-Related Complex (ARC)
03/2014
1Acquired Immunodeficiency Syndrome (AIDS)
01/2014
1Alzheimer Disease (Alzheimer's Disease)
12/2011
1Amyloid Neuropathies (Amyloid Neuropathy)
08/2011
1Asthma (Bronchial Asthma)
08/2005

Drug/Important Bio-Agent (IBA)

2Phosphotransferases (Kinase)IBA
11/2020 - 01/2019
2FebuxostatFDA Link
08/2011 - 04/2009
1ethyleneIBA
10/2023
1RNA (Ribonucleic Acid)IBA
10/2023
1Proteins (Proteins, Gene)FDA Link
01/2023
15- (3- ethynylphenylamino)pyrimido(4,5- c)quinoline- 8- carboxylic acidIBA
11/2020
1Lysine (L-Lysine)FDA Link
01/2018
1Histones (Histone)IBA
01/2018
1caramiphenIBA
04/2015
1Cholinergic Antagonists (Anticholinergics)IBA
04/2015
1CCR5 Receptors (CCR5 Receptor)IBA
02/2015
1SootIBA
03/2014
16-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
03/2014
1Chemokine ReceptorsIBA
01/2014
1dragmacidin DIBA
12/2011
1tafamidisIBA
08/2011
1Xanthine OxidaseIBA
08/2011
1texalineIBA
08/2011
1ethylene sulfide (thiirane)IBA
08/2005
1CDP 840IBA
08/2005

Therapy/Procedure

3Therapeutics
11/2020 - 01/2018